پلتفرم‌های مراقبت دیجیتال و همراه در مسیر درمان با GLP-1: چه عواملی به نتیجه بهتر کمک می‌کنند و چرا بیماران درمان را قطع می‌کنند؟

Conclusion:

Digital GLP-1 care can support substantial weight loss, especially among patients who remain engaged and on treatment. But the population-level value of these services is constrained by low persistence and by barriers that extend beyond software. The evidence favors comprehensive programs that combine medication management with self-monitoring, coaching, personalized feedback, safety escalation, and multidisciplinary follow-up. It also argues for more transparent reporting. Weight loss among completers should always be presented alongside retention, medication persistence, discontinuation reasons, and post-treatment outcomes. The future of GLP-1 digital care will not be determined by which platform generates the most notifications. It will be determined by which platforms help the greatest number of appropriate patients navigate treatment safely, sustain benefit, and receive continuous support when circumstances change. SALUNOTE's contribution to that future is deliberately bounded: a calm, bilingual companion for diet, movement, habits, and self-recorded progress, with medication and medical judgment left to the patient's own clinician. Readers can explore the current product at salunote.com.